Rovi and Moderna

World economy 5th March 2024

FDA authorises Laboratorios Rovi to export vaccines manufactured with mRNA technology to the US

Bankinter: After a long process of inspection of its factories, the Company has obtained this authorisation, which makes it possible to manufacture in Spain and sell in the United States Moderna’s anti-COVID vaccine and a next generation of vaccines that Moderna plans to introduce in the market based on the same technology. Assessment: Very positive news that improves the outlook for Rovi’s third party manufacturing, which already represents approximately 50%…

Spanish economy, Spanish Small & Mid Caps 19th November 2020

ROVI’s Target Price To Rise By 6.5 €/shr To 36 €/shr After Moderna’s Vaccine News

Four months ago, Spanish ROVI reached an agreement with Moderna for the filling and packaging of its vaccine. Since then ROVI’s capitalisation has increased by more than €750 M (up 53%). So far this month alone, the stock price has risen by 27%. With a central scenario of about 550 M of Moderna’s vaccines per year outside the US and Japan, the unit income for ROVI would be 0.75 €/vaccine (3.5% higher than the total price of the vaccine) which means a T.P. rise of +6, 5 €/shr. (+22% vs. before) up to 36 €/acc.

Markets, Spanish Small & Mid Caps 10th July 2020

Rovi To Manufacture Moderna’s COVID-19 Vaccine

US biotech firm Moderna and Spanish laboratory Rovi announced a collaboration agreement to carry out the filling and finishing of a candidate vaccine for Covid-19 (mRNA-1273) outside the US. ROVI will carry out the phases of vial filling and completion. Thus it will acquire a new production line and the necessary equipment for formulation, filling, inspection and labelling, as well as the additional personnel required.The new line would be owned by Rovi, but Moderna will make the investment.